The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: Vascular endothelial growth factor is a key promoter of tumor progression in cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti–vascular endothelial growth factor monoclonal antibody. Patients and Methods: Eligible patients had recurrent cervical cancer, measurable disease, and GOG performance status ≤ 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and toxicity. Results: Forty-six patients were enrolled (median age, 46 years); 38 patients (82.6%) received prior radiation as well as either one (n = 34, 73.9%) or two (n = 12, 26.1%) prior cytotoxic regimens for recurrent disease. Grade 3 or 4 adverse events at least possibly related to bevacizumab included hypertension (n = 7), thrombo-embolism (n = 5), GI (n = 4), anemia (n = 2), other cardiovascular (n = 2), vaginal bleeding (n = 1), neutropenia (n = 1), and fistula (n = 1). One grade 5 infection was observed. Eleven patients (23.9%; two-sided 90% CI, 14% to 37%) survived progression free for at least 6 months, and five patients (10.9%; two-sided 90% CI, 4% to 22%) had partial responses. The median response duration was 6.21 months (range, 2.83 to 8.28 months). The median PFS and overall survival times were 3.40 months (95% CI, 2.53 to 4.53 months) and 7.29 months (95% CI, 6.11 to 10.41 months), respectively. This compared favorably with historical phase II GOG trials in this setting. Conclusion: Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer and merits phase III investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,065
Long, H. J., Bundy, B. N., Grendys, E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., & Fiorica, J. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.021 · Cited by 556
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Pentecost, M. J., Criqui, M. H., Dorros, G., Goldstone, J., Johnston, K. W., Martin, E. C., Ring, E. J., & Spies, J. B. (1994) · Circulation · doi:10.1161/01.cir.89.1.511 · Cited by 303
Monk, B. J., Tewari, K. S., & Koh, W.-J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8324 · Cited by 261
Self-citationRose, P. G., Blessing, J. A., Gershenson, D. M., & McGehee, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2676 · Cited by 206
Cited by
Cervical cancer therapies: Current challenges and future perspectives
Burmeister, C. A., Khan, S. F., Schäfer, G., Mbatani, N., Adams, T., Moodley, J., & Prince, S. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200238 · Cited by 474
Monk, B. J., Mas Lopez, L., Zarba, J. J., Oaknin, A., Tarpin, C., Termrungruanglert, W., Alber, J. A., Ding, J., Stutts, M. W., & Pandite, L. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9571 · Cited by 264
Self-citationLan, C., Shen, J., Wang, Y., Li, J., Liu, Z., He, M., Cao, X., Ling, J., Huang, J., Zheng, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01920 · Cited by 210
Pembrolizumab for advanced cervical cancer: Safety and efficacy
De Felice, F., Giudice, E., Bolomini, G., Distefano, M. G., Scambia, G., Fagotti, A., & Marchetti, C. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1850279 · Cited by 30
Metadata
- Authors
- Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-03-01
- Volume
- 27
- Issue
- 7
- Pages
- 1069-1074
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170825221
- Cited by
- 346
- References
- 15
- FWCI
- 27.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. https://app.cochat.ai/papers/10.1200/jco.2008.18.9043
- The paper
- Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009). Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.18.9043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
